Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

Simple item page
dc.coverageDOI: 10.1177/17562872211029779
dc.creatorRenner, Alex
dc.creatorBurotto, Mauricio
dc.creatorValdes, Jose Miguel
dc.creatorRoman, Juan Carlos
dc.creatorWalton-Diaz, Annerleim
dc.date2021
dc.date.accessioned2025-11-18T19:52:12Z
dc.date.available2025-11-18T19:52:12Z
dc.description<p>Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/d5519a89-3f43-4b9c-9b65-4d401f5411fb
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/57603
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.13 (2021)
dc.subjectbladder cancer
dc.subjectimmune checkpoint inhibitor
dc.subjectimmunotherapy
dc.subjectmuscle invasive
dc.subjectneoadjuvant
dc.subjectSDG 3 - Good Health and Well-being
dc.titleNeoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?eng
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections
PURE